azacitidine has been researched along with 4-phenylbutyric acid in 19 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (5.26) | 18.2507 |
2000's | 11 (57.89) | 29.6817 |
2010's | 6 (31.58) | 24.3611 |
2020's | 1 (5.26) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Fibach, E; Prasanna, P; Rodgers, GP; Samid, D | 1 |
Carpentieri, D; Flake, AW; Hayashi, S; Ikegaki, N; Kim, DY; Kung, B; Riceberg, JS; Robinson, ME; Tang, XX; Titus, TB | 1 |
Camacho, LH; Chanel, S; Guernah, I; Maslak, P; Nimer, S; Pandolfi, PP; Soignet, S; Warrell, R | 1 |
Chuang, JC; Coetzee, GA; Egger, G; Friedman, JM; Jones, PA; Liang, G; Saito, Y | 1 |
Aparicio, AM; Egger, G; Escobar, SG; Jones, PA | 1 |
Bergeron, A; Fradet, Y; Larue, H; Picard, V | 1 |
Bruserud, Ø; Ryningen, A; Stapnes, C | 1 |
Bueno, MJ; Calin, GA; Cigudosa, JC; Croce, CM; Fernández-Piqueras, J; Gómez de Cedrón, M; Malumbres, M; Pérez de Castro, I; Santos, J | 1 |
Chihara, Y; Chuang, JC; Egger, G; Friedman, JM; Liang, G; Saito, Y | 1 |
Hibi, T; Kanai, Y; Matsuzaki, J; Nakagawa, I; Saito, Y; Suzuki, H; Tsugawa, H | 1 |
Ibrahim, SM; Kunz, M; Schultz, J; Vera, J | 1 |
Ambinder, RF; Baker, SD; Carducci, MA; Donehower, RC; Gilbert, J; Gore, S; Herman, JG; Jiemjit, A; Lin, J; Rudek, MA; Zhao, M; Zwiebel, JA | 1 |
Dash, S; Feitelson, M; Han, C; Lim, K; Lu, D; Song, K; Wu, T; Zhang, J | 1 |
Busch, M; Dünker, N; Philippeit, C | 1 |
Hasegawa, T; Hirata, K; Isosaka, M; Kai, M; Kanda, T; Maruyama, R; Niinuma, T; Nishida, T; Nobuoka, T; Nojima, M; Shinomura, Y; Suzuki, H; Taguchi, T; Tokino, T; Yamamoto, E | 1 |
He, C; Jiang, H; Xu, R; Zhao, X; Zhong, Z | 1 |
Kiaris, H; Mihailidou, C; Papavassiliou, AG | 1 |
1 review(s) available for azacitidine and 4-phenylbutyric acid
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for azacitidine and 4-phenylbutyric acid
Article | Year |
---|---|
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
Topics: Acetylation; Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; DNA Methylation; Drug Administration Schedule; Drug Therapy, Combination; Female; Histones; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Pilot Projects; Transcription, Genetic; Treatment Outcome | 2006 |
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Histone Acetyltransferases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phenylbutyrates; Treatment Outcome | 2009 |
16 other study(ies) available for azacitidine and 4-phenylbutyric acid
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.
Topics: Anemia, Sickle Cell; Azacitidine; beta-Thalassemia; Blotting, Northern; Butyrates; Butyric Acid; Cell Division; Cells, Cultured; DNA Probes; Erythrocytes; Fetal Hemoglobin; Hematopoietic Stem Cells; Humans; Hydroxyurea; Kinetics; Phenylacetates; Phenylbutyrates; Reference Values | 1993 |
Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Boronic Acids; Caspases; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Nude; Mice, SCID; Neoplasm Proteins; Neuroblastoma; Phenylbutyrates; Proteasome Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.
Topics: Azacitidine; Cell Line, Tumor; Chromatin; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; MicroRNAs; Phenylbutyrates; Promoter Regions, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-6 | 2006 |
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Fibroblasts; Histone Deacetylase Inhibitors; Histones; Humans; Neoplasms; Phenylbutyrates | 2007 |
MAGE-A9 mRNA and protein expression in bladder cancer.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; Gene Expression; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Male; Neoplasm Proteins; Phenylbutyrates; Protein Isoforms; Pyridines; RNA, Messenger; Testicular Neoplasms; Urinary Bladder Neoplasms | 2007 |
Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Proliferation; Decitabine; DNA, Mitochondrial; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Thymidine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2007 |
Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.
Topics: 3' Untranslated Regions; Animals; Azacitidine; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 14; Chromosomes, Mammalian; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Loss of Heterozygosity; Lymphoma, T-Cell; Lymphoproliferative Disorders; Mice; Mice, Inbred C57BL; MicroRNAs; Phenylbutyrates; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Proto-Oncogene Proteins c-abl; Time Factors; Transfection; Up-Regulation; Whole-Body Irradiation | 2008 |
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells.
Topics: Antineoplastic Agents; Azacitidine; Calcium-Binding Proteins; Cell Line, Tumor; Decitabine; EGF Family of Proteins; Endothelial Growth Factors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; MicroRNAs; Neoplasms; Phenylbutyrates; Promoter Regions, Genetic; Prostatic Neoplasms; Up-Regulation; Urinary Bladder Neoplasms | 2009 |
Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.
Topics: Alu Elements; Apoptosis; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Chromosomes, Human, Pair 19; Decitabine; DNA Methylation; DNA Polymerase II; DNA Polymerase III; Down-Regulation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Phenylbutyrates; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms | 2009 |
14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Movement; Cellular Senescence; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Exonucleases; Exoribonucleases; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Melanoma; Neoplasm Metastasis; Neoplasm Proteins; Phenylbutyrates; RNA, Messenger | 2009 |
Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells.
Topics: Azacitidine; Carcinoma, Hepatocellular; Decitabine; Epigenesis, Genetic; Hep G2 Cells; Hepatitis C; Humans; Liver Neoplasms; Methyltransferases; MicroRNAs; Phenylbutyrates; PPAR gamma; Promoter Regions, Genetic; Repressor Proteins; Trans-Activators; Viral Regulatory and Accessory Proteins | 2013 |
Epigenetic control of trefoil factor family (TFF) peptide expression in human retinoblastoma cell lines.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Primers; Epigenesis, Genetic; Female; Humans; Male; Peptide Fragments; Peptides; Phenylbutyrates; Polymerase Chain Reaction; Promoter Regions, Genetic; Retinoblastoma; Trefoil Factor-1; Trefoil Factor-2; Trefoil Factor-3; Tumor Suppressor Proteins | 2014 |
A Screen for Epigenetically Silenced microRNA Genes in Gastrointestinal Stromal Tumors.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Neoplasm Proteins; Phenylbutyrates; Receptor, Platelet-Derived Growth Factor beta; RNA, Neoplasm | 2015 |
Demethylation of miR-10b plays a suppressive role in ccRCC cells.
Topics: Azacitidine; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; MicroRNAs; Neoplasm Invasiveness; Nuclear Proteins; Phenylbutyrates; Promoter Regions, Genetic; Time Factors; Transfection; Twist-Related Protein 1 | 2015 |
Cell-autonomous cytotoxicity of type I interferon response
Topics: Animals; Azacitidine; Blotting, Western; Cell Death; Cell Survival; Cells, Cultured; Ciclopirox; Endoplasmic Reticulum Stress; Enzyme-Linked Immunosorbent Assay; Interferon Type I; Mice; Mice, Inbred C57BL; Phenylbutyrates; Pyridones; Taurochenodeoxycholic Acid; Unfolded Protein Response | 2017 |